Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

Christian F. Ockenhouse, Pei Fang Sun, David E. Lanar, Bruce T. Wellde, B. Ted Hall, Kent Kester, Jose A. Stoute, Alan Magill, Urszula Krzych, Linda Farley, Robert A. Wirtz, Jerald C. Sadoff, David C. Kaslow, Sanjai Kumar, L. W. Preston Church, James M. Crutcher, Benjamin Wizel, Stephen Hoffman, Ajit Lalvani, Adrian V.S. HillJohn A. Tine, Kenneth P. Guito, Charles De Taisne, Robin Anders, Toshihiro Horii, Enzo Paoletti, W. Ripley Ballou

Research output: Contribution to journalArticlepeer-review

200 Scopus citations

Abstract

Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine trial in human volunteers. Malaria genes inserted into the NYVAC genome encoded proteins from all stages of the parasite's life cycle. Volunteers received three immunizations of two different dosages of NYVAC- Pf7. The vaccine was safe and well tolerated but variably immunogenic. While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers. Of the 35 volunteers challenged with the bite of 5 P. falciparum-infected Anopheles mosquitoes, 1 was completely protected, and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.

Original languageEnglish (US)
Pages (from-to)1664-1673
Number of pages10
JournalJournal of Infectious Diseases
Volume177
Issue number6
DOIs
StatePublished - 1998

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria'. Together they form a unique fingerprint.

Cite this